Myriad Genetics, Inc.
MYGN
$10.18
-$0.34-3.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.12% | 11.15% | 15.26% | 11.59% | 10.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.12% | 11.15% | 15.26% | 11.59% | 10.57% |
| Cost of Revenue | -3.08% | 10.24% | 11.42% | 9.12% | 14.29% |
| Gross Profit | 11.78% | 11.54% | 17.02% | 12.79% | 8.96% |
| SG&A Expenses | -5.82% | 2.20% | 2.99% | -3.70% | -8.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.40% | 6.16% | 7.60% | 1.05% | -3.73% |
| Operating Income | 43.09% | 31.01% | 31.22% | 40.00% | 47.59% |
| Income Before Tax | -21.05% | 65.36% | 67.96% | 50.76% | 38.00% |
| Income Tax Expenses | 409.09% | 800.00% | -- | -95.24% | 88.78% |
| Earnings from Continuing Operations | -36.22% | 63.95% | 68.39% | 52.47% | 26.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.22% | 63.95% | 68.39% | 52.47% | 26.24% |
| EBIT | 43.09% | 31.01% | 31.22% | 40.00% | 47.59% |
| EBITDA | 83.66% | 87.36% | 57.21% | 54.98% | 65.46% |
| EPS Basic | -28.73% | 67.52% | 71.49% | 57.02% | 30.17% |
| Normalized Basic EPS | 47.28% | 36.39% | 40.20% | 50.04% | 48.99% |
| EPS Diluted | -27.80% | 67.59% | 71.15% | 56.90% | 29.36% |
| Normalized Diluted EPS | 47.28% | 36.39% | 40.20% | 50.04% | 48.99% |
| Average Basic Shares Outstanding | 5.81% | 10.99% | 10.89% | 10.58% | 5.64% |
| Average Diluted Shares Outstanding | 5.81% | 10.99% | 10.89% | 10.58% | 5.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
